BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cazzola M, Puxeddu E, Ora J, Rogliani P. Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers. Mol Diagn Ther 2019;23:603-14. [PMID: 31363933 DOI: 10.1007/s40291-019-00413-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Agustí A, Christenson S, Han M, Singh D. New Frontiers in Chronic Obstructive Pulmonary Disease: Where Are We Heading? EMJ Respir 2022. [DOI: 10.33590/emjrespir/10038710] [Reference Citation Analysis]
2 Cazzola M, Rogliani P, Matera MG. Unmet Needs and the Future of Asthma-Chronic Pulmonary Obstructive Disease Overlap. Immunology and Allergy Clinics of North America 2022. [DOI: 10.1016/j.iac.2022.04.006] [Reference Citation Analysis]
3 Cazzola M, Rogliani P, Calzetta L, Ora J, Matera MG. A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. Expert Rev Clin Pharmacol 2022. [PMID: 35475762 DOI: 10.1080/17512433.2022.2071700] [Reference Citation Analysis]
4 Klont F, Horvatovich P, Bowler RP, van Rikxoort E, Charbonnier JP, Kwiatkowski M, Lynch DA, Humphries S, Bischoff R, Ten Hacken NHT, Pouwels SD. Plasma sRAGE levels strongly associate with centrilobular emphysema assessed by HRCT scans. Respir Res 2022;23:15. [PMID: 35073932 DOI: 10.1186/s12931-022-01934-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cazzola M, Rogliani P, Laitano R, Calzetta L, Matera MG. Beyond Dual Bronchodilation – Triple Therapy, When and Why. COPD 2022;Volume 17:165-80. [DOI: 10.2147/copd.s345263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Cazzola M. Moving to a Personalized Approach in Respiratory Medicine. From Academic Research to Regulatory Intervention. Front Drug Saf Regul 2021;1. [DOI: 10.3389/fdsfr.2021.752581] [Reference Citation Analysis]
7 Andreeva E, Pokhasnikova M, Lebedev A, Moiseeva I, Kozlov A, Kuznetsova O, Degryse JM. Inflammatory parameters and pulmonary biomarkers in smokers with and without chronic obstructive pulmonary disease (COPD). J Thorac Dis 2021;13:4812-29. [PMID: 34527321 DOI: 10.21037/jtd-20-1580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Faiz A, Rathnayake SNH, Ten Hacken NHT, Guryev V, van den Berge M, Pouwels SD. Single-nucleotide polymorphism rs2070600 regulates AGER splicing and the sputum levels of the COPD biomarker soluble receptor for advanced glycation end-products. ERJ Open Res 2021;7:00947-2020. [PMID: 34195255 DOI: 10.1183/23120541.00947-2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
9 Barnes PJ, Anderson GP, Fagerås M, Belvisi MG. Chronic lung diseases: prospects for regeneration and repair. Eur Respir Rev 2021;30:200213. [PMID: 33408088 DOI: 10.1183/16000617.0213-2020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
10 Karampitsakos T, Dimakou K, Papaioannou O, Chrysikos S, Kaponi M, Bouros D, Tzouvelekis A, Hillas G. The role of increased red cell distribution width as a negative prognostic marker in patients with COPD. Pulm Pharmacol Ther 2020;60:101877. [PMID: 31843703 DOI: 10.1016/j.pupt.2019.101877] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]